Alan Meds vs Vyora Wellness
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Vyora Wellness
Best for patients wanting coaching-inclusive compounded GLP-1 programsStarting at $299/mo
Side-by-Side Comparison
| Feature | Alan Meds | Vyora Wellness |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.0/10 |
| Starting Price | ✓$99/mo | $299/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | ✓5 features | 4 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Vyora Wellness
Pros
- ✓LegitScript certified
- ✓Price includes nutritional guidance, 24/7 coaching, and community access
- ✓Both semaglutide and tirzepatide available
- ✓BMI 25+ eligibility threshold (lower than some competitors)
Cons
- ✗State availability not publicly disclosed
- ✗Pricing is above average ($299–$399/mo) compared to competitors
- ✗Compounded only — no brand-name options
- ✗Broader platform (metabolic, longevity, topical products)
Our Verdict
Alan Meds edges out Vyora Wellness with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Vyora Wellness remains a solid alternative, especially if you're looking for patients wanting coaching-inclusive compounded GLP-1 programs.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.